来源：oncologystat
分享：阳光明媚
食管癌和食管胃结合部癌
Epidemiology 流行病学
1.Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence ofesophageal and gastric carcinoma in the United States. Cancer. 1998; 83:2049-2053（全文）.
2.Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgicaltherapies for gastroesophageal reflux disease: follow-up of a randomized controlledtrial. JAMA. 2001; 285(18): 2331-2338. （全文）
3.Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastricatrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagusand adenocarcinoma of the gastric cardia. J Natl Cancer Inst. 2004; 96:388-396.（全文）
Barrett’s Esophagus Barrett食管
4.Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, andesophageal cancer: scientific review.JAMA.2002; 287:1972-1981（全文）.
5.Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma amongpatients with Barrett's esophagus. NEngl J Med. 2011; 365:1375-1383（全文）.
6.Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’sesophagus with dysplasia. NEngl J Med. 2009; 28: 2277-2288（全文）.
Staging 分期
7.Siewert JR, Feith M, M. Werner, M. Adenocarcinoma of the Esophagogastric Junction;Results of Surgical Therapy Based on Anatomical/Topographic Classification in1,002 Consecutive Patients. Ann Surg. 2000 September; 232(3):353–361（全文）.
8.van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations foroesophageal cancer: a meta-analysis.Br J Cancer. 2008; 98:547-557（全文）.
9.Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomographyfor the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000; 18:3202-3210（全文）.
Surgery 手术
10.Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracicresection compared with limited transhiatal resection for adenocarcinoma of theesophagus. N Engl J Med. 2002; 347(21):1662-1669（全文）.
11.Chang AC, Ji H, Birkmeyer NJ, et al. Outcomes after transhiatal andtransthoracic esophagectomy for cancer. Ann Thorac Surg. 2008; 85(2):424-429.
12.Wolff CS, Castillo SF, Larson DR, et al. Ivor Lewis approach is superior totranshiatal approach in retrieval of lymph nodes at esophagectomy. Dis Esophagus. 2008; 21:328-333.
13.Groth SS, Whitson BA, Li Z, et al. Determination of the ideal number of lymphnodes to examine to optimize survival in patients with esophageal carcinoma:Data from the surveillance epidemiology and end results database. J Clin Oncol(Meeting Abstracts). 2008; 26: 4528.
14.Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophagealcancer. Ann Surg. 2010; 251(1): 46-50.
LocoregionalDisease Treatment 局限性疾病治疗
15.Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy andradiotherapy compared with radiotherapy alone in patients with cancer of theesophagus. N Engl J Med. 1992; 326:1593-1598（全文）.
16.Allum WH, Stenning SP, Bancewicz J. Long-term results of a randomized trial ofsurgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009 Oct20;27(30):5062-7（全文）.
17.Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advancedesophageal cancer: long-term follow-up of a prospective randomized trial (RTOG85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281:1623-1627（全文）.
18.Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgeryin patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol.2005; 23:2310-2317（全文）.
19.Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgerycompared with chemoradiation alone in squamour cancer of the esophagus: FFCD9102. J Clin Oncol. 2007; 25(10): 1160-1168（全文）.
20.Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911(USA Intergroup 113): a random assignment trial comparison of chemotherapyfollowed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol.2007; 25(24): 3719-3725（全文）.
21.Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versussurgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11-20（全文）.
22.Sjoquist KM, Burmeister BH, Smithers BM. Survival after neoadjuvantchemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: anupdated meta-analysis. Lancet Oncol. 2011 Jul;12(7):681-92.
23.Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodalitytherapy with cisplatin, fluorouracil, radiotherapy, and surgery compared withsurgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26:1086-1092（全文）.
24.van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. PreoperativeChemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med2012; 366:2074-2084 May 31, 2012.
25.Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperativechemotherapy compared with chemoradiotherapy in patients with locally advancedadenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009; 27(6): 851-856（全文）.
26.Ychou M, Boige V, Pignon JP. Perioperative chemotherapy compared with surgeryalone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCDmulticenter phase III trial. J Clin Oncol. 2011;29(13):1715（全文）.
Unresectable/MetastaticDisease Treatment
不可切除/转移性疾病治疗
26.Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastriccancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18): 2903-2909（全文）.
27.Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin,cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexatein advanced esophagogastric cancer. J Clin Oncol. 1997; 15(1): 261-267.
28.Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparingmitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU)with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002; 1996-2004（全文）.
29.Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxeland cisplatin plus fluorouracil compared with cisplatin and fluorouracil asfirst-line therapy for advanced gastric cancer: a report of the V325 StudyGroup. J Clin Oncol. 2006; 24(31):4991-4997(全文).
30.Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin foradvanced esophagogastric cancer. N Engl J Med. 2008; 358(1): 36-46（全文）.
31.Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparingirinotecan combined with 5-fluorouracil and folinic acid to cisplatin combinedwith 5-fluorouracil in chemotherapy naïve patients with advaced adenocarcinomaof the stomach or esophagogastric junction. Ann Oncol. 2008; 19(8): 1450-1457（全文）.
32.Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastaticgastroesophageal adenocarcinoma with fluorouracil, leucovorin plus eitheroxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft InternistischeOnkologie. J Clin Oncol. 2008; 26(9): 1435-1442（全文）.
33.Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomizedphase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) pluscetuximab in metastatic esophageal and GE juncion cancer. J Clin Oncol(Meeting Abstracts). 2010; 28: 4006.
34.Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination withchemotherapy versus chemotherapy alone for treatment of HER2-positive advancedgastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label,randomised controlled trial. Lancet. 2010; 376(9742): 687-697.
35.Kang YK, Kang WK, Shin DB. Capecitabine/cisplatin versus5-fluorouracil/cisplatin as first-line therapy in patients with advancedgastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73（全文）.
责任编辑：Lilith
苏公网安备32059002004080号
